Stoke Therapeutics, Inc. (NASDAQ:STOK - Free Report) - Cantor Fitzgerald raised their FY2025 earnings per share (EPS) estimates for shares of Stoke Therapeutics in a research note issued on Thursday, March 20th. Cantor Fitzgerald analyst C. Duncan now anticipates that the company will post earnings of $0.03 per share for the year, up from their previous estimate of ($2.40). Cantor Fitzgerald has a "Overweight" rating on the stock. The consensus estimate for Stoke Therapeutics' current full-year earnings is ($2.01) per share.
Other equities analysts have also issued research reports about the company. HC Wainwright reissued a "buy" rating and issued a $47.00 target price on shares of Stoke Therapeutics in a research note on Wednesday, March 19th. Chardan Capital reissued a "buy" rating and set a $24.00 price objective on shares of Stoke Therapeutics in a research note on Wednesday, March 19th. Finally, Needham & Company LLC reaffirmed a "buy" rating and issued a $22.00 target price on shares of Stoke Therapeutics in a research note on Tuesday, March 18th. Seven investment analysts have rated the stock with a buy rating and one has given a strong buy rating to the stock. Based on data from MarketBeat, Stoke Therapeutics currently has an average rating of "Buy" and a consensus target price of $24.67.
Check Out Our Latest Analysis on STOK
Stoke Therapeutics Trading Up 0.7 %
Shares of NASDAQ:STOK traded up $0.05 during midday trading on Monday, hitting $7.45. The company had a trading volume of 1,155,600 shares, compared to its average volume of 762,864. Stoke Therapeutics has a 12 month low of $7.18 and a 12 month high of $17.58. The firm has a fifty day simple moving average of $9.40 and a 200 day simple moving average of $11.27. The stock has a market cap of $402.88 million, a price-to-earnings ratio of -3.55 and a beta of 0.99.
Stoke Therapeutics (NASDAQ:STOK - Get Free Report) last announced its quarterly earnings data on Monday, March 24th. The company reported ($0.18) earnings per share for the quarter, beating the consensus estimate of ($0.56) by $0.38. The business had revenue of $22.61 million for the quarter, compared to analyst estimates of $4.20 million. Stoke Therapeutics had a negative net margin of 629.90% and a negative return on equity of 54.45%.
Insider Transactions at Stoke Therapeutics
In other news, insider Barry Ticho sold 3,884 shares of the stock in a transaction that occurred on Tuesday, March 18th. The stock was sold at an average price of $8.67, for a total transaction of $33,674.28. Following the transaction, the insider now owns 63,962 shares in the company, valued at approximately $554,550.54. This trade represents a 5.72 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. Also, Director Edward M. Md Kaye sold 10,382 shares of the business's stock in a transaction on Tuesday, March 18th. The shares were sold at an average price of $8.67, for a total value of $90,011.94. Following the completion of the sale, the director now owns 148,253 shares of the company's stock, valued at $1,285,353.51. This trade represents a 6.54 % decrease in their ownership of the stock. The disclosure for this sale can be found here. In the last 90 days, insiders sold 16,532 shares of company stock worth $143,332. 11.30% of the stock is owned by insiders.
Institutional Trading of Stoke Therapeutics
Several hedge funds and other institutional investors have recently bought and sold shares of the business. KLP Kapitalforvaltning AS bought a new position in shares of Stoke Therapeutics during the fourth quarter worth approximately $63,000. Teacher Retirement System of Texas acquired a new stake in Stoke Therapeutics during the fourth quarter worth approximately $113,000. China Universal Asset Management Co. Ltd. acquired a new position in Stoke Therapeutics in the 4th quarter valued at $124,000. Tower Research Capital LLC TRC raised its holdings in Stoke Therapeutics by 70.1% in the 4th quarter. Tower Research Capital LLC TRC now owns 11,930 shares of the company's stock valued at $132,000 after acquiring an additional 4,918 shares in the last quarter. Finally, Invesco Ltd. bought a new stake in shares of Stoke Therapeutics during the 4th quarter valued at $133,000.
About Stoke Therapeutics
(
Get Free Report)
Stoke Therapeutics, Inc, an early-stage biopharmaceutical company, develops medicines to treat the underlying causes of severe genetic diseases in the United States. The company utilizes its proprietary targeted augmentation of nuclear gene output to develop antisense oligonucleotides to selectively restore protein levels.
Recommended Stories
Before you consider Stoke Therapeutics, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Stoke Therapeutics wasn't on the list.
While Stoke Therapeutics currently has a Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Nuclear energy stocks are roaring. It's the hottest energy sector of the year. Cameco Corp, Paladin Energy, and BWX Technologies were all up more than 40% in 2024. The biggest market moves could still be ahead of us, and there are seven nuclear energy stocks that could rise much higher in the next several months. To unlock these tickers, enter your email address below.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
